

STROBE Statement - Checklist of items that should be included in reports of *cross-sectional* studies

	Item No	Recommendation	Reported on Page Number / Line Number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1 Line 1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2-3 Line 53-78
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 5-7 Line 79-129
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 7 Line 131-136
Methods			
Study design	4	Present key elements of study design early in the paper	Page 7 Line 138-141
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 7-8 Line 143-158
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Page 8-9 Line 160-196
Variable	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 9 Line 182-196 Page 10 Line 197-201
Data sources/ measurement	8 *	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 7-8 Line 143-152
Bias	9	Describe any efforts to address potential sources of bias	Page 8-9

			Line 171-181
Study size	10	Explain how the study size was arrived at	Page 11 Line 235-240
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 8 Line 160-168
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 10-11 Line 202-225
		(b) Describe any methods used to examine subgroups and interactions.	Page 10 Line 210-216
		(c) Explain how missing data were addressed	Page 10 Line 203-204
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13 *	(a) Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	Page 11 Line 235-240
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	Page 10 Line 240
Descriptive data	14 *	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 11-12 Line 241-268
		(b) Indicate number of participants with missing data for each variable of interest	Tables 1,2,3
Outcome data	15 *	Report numbers of outcome events or summary measures	Page 13 Line 269-281
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence	Page 13 Line 269-281

		interval). Make clear which confounders were adjusted for and why they were included	Page 13-14 Line 282-301 Tables 1,2,3,4
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses.	Supplement Tables A, B,C
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 14-12 Line 303-307
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 19 Line 418-440
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 14-18 Line 308-417
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 19 Line 430-433
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 26 Line 680-681

Article information: <https://dx.doi.org/10.21037/apm-22-418>

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version.